Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2013

Open Access 01-06-2013 | Original Paper

High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients

Authors: Aleksandra Butrym, Miroslaw Majewski, Justyna Dzietczenia, Kazimierz Kuliczkowski, Grzegorz Mazur

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. It is characterized by heterogeneous clinical course of the disease and new prognostic factors are still needed. CD74 plays an important role in signal transduction in B cell proliferation and survival pathway. CD74 expression has been shown in solid tumors and has been connected with poor prognosis and tumor progression. The aim of the study was to evaluate the expression of CD74 in chronic lymphocytic leukemia patients with combination with other known prognostic factors. Expression of CD74 was determined in 90 patients and 28 healthy controls. CD74 expression was significantly higher in CLL group than in controls. There was positive correlation between CD74 and ZAP70 expression (p = 0.008). High expression of CD74 was positively correlated with more advanced stage of the disease (p = 0.02). No correlation was shown between CD74 and sex, mutational status IgVH and time to first treatment.
Literature
1.
Rai KR, Wasil T. History of chronic lymphocytic leukemia. Chronic lymphoid leukemias second edition. New York: National Cancer Institiute; 2001. p. 1–7.
2.
3.
Bazargan A, Tam CS, Keating MJ. Predicting survival of chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12:393–403.PubMedCrossRef
4.
Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev. 2010;10:37–50.
5.
Houlston RS, Sellick G, Yuille M, Matutes E, Catovsky D. Causation of chronic lymphocytic leukemia–insights from familial disease. Leuk Res. 2003;27:871–6.PubMedCrossRef
6.
Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13:5556s–63s.PubMedCrossRef
7.
Matza D, Wolstein O, Dikstein R, Schachar I. Invariant chain induces B cell maturation by activating a TAFII105-NF- κB-dependent transcription program. J Biol Chem. 2001;276:27203–6.PubMedCrossRef
8.
Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma. 2011;52:1446–54.PubMedCrossRef
9.
Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197:1467–76.PubMedCrossRef
10.
Li GQ, Xie J, Lei XY, Zhang L. Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3 K/Akt pathway. World J Gastroenterol. 2009;15:5541–8.PubMedCrossRef
11.
Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma cells and is promising target for therapy. Clin Cancer Res. 2004;10:6606–11.PubMedCrossRef
12.
Ishigami S, Natsugoe S, Tokuda K, et al. Invariant chain expression in gastric cancer. Cancer Lett. 2001;168:87–91.PubMedCrossRef
13.
Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158:1639–51.PubMedCrossRef
14.
McClelland M, Zhao L, Carskadon S, Arenberg D. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol. 2009;174:638–46.PubMedCrossRef
15.
Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2000;8:210–5.PubMedCrossRef
16.
Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79:2115–24.PubMedCrossRef
17.
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med. 2000;343:1910–6.CrossRef
18.
Seiffert M, Dietrich S, Jethwa A, Glimm H, Lichter P, Zenz T. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1023–31.PubMedCrossRef
19.
Jäger U, Shehata M, Heintel D, et al. Genetics in chronic lymphocytic leukaemia: impact for prognosis and treatment decisions. Hematology education: the education program for the annual congress of the European Hematology Association. 2007;1:115–121.
20.
Ghia P, Stomatopoulos K, Belessi C, et al. European Research Initiative on CLL: ERIC recommendations in IGVH gene mutational status analysis in chronic lymphocytic leukemia [editorial]. Leukemia. 2007;21:1–3.PubMedCrossRef
21.
Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 2005;16:5061–9.PubMedCrossRef
22.
Binsky I, Lantner F, Grabovsky V, et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol. 2010;184:4761–9.PubMedCrossRef
23.
Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107:4807–16.PubMedCrossRef
24.
Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA. 2007;104:13408–13.PubMedCrossRef
25.
Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104:3705–11.PubMedCrossRef
26.
Frölich D, Blaßfeld D, Reiter K, et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther. 2012;14:R54.PubMedCrossRef
27.
Lantner F, Starlets D, Gore Y, et al. CD74 induces TAp63 expression leading to B-cell survival. Blood. 2007;110:4303–11.PubMedCrossRef
28.
Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008;283:2784–92.PubMedCrossRef
29.
Souwer Y, Chamuleau ME, van de Loosdrecht AA, et al. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival. Br J Haematol. 2009;145:334–43.PubMedCrossRef
30.
Gordin M, Tesio M, Cohen S, et al. C-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol. 2010;185:2020–31.PubMedCrossRef
31.
Maharshak N, Cohen S, Lantner F, et al. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol. 2010;16:3258–66.PubMedCrossRef
32.
Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923–30.PubMedCrossRef
33.
Beswick EJ, Reyes VR. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol. 2009;15:2855–61.PubMedCrossRef
34.
Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin Immunol. 2002;14:19–26.PubMedCrossRef
35.
Fruman DA. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004;16:314–20.PubMedCrossRef
36.
Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7:122–33.PubMedCrossRef
Metadata
Title
High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients
Authors
Aleksandra Butrym
Miroslaw Majewski
Justyna Dzietczenia
Kazimierz Kuliczkowski
Grzegorz Mazur
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0560-5

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue

Original Paper

Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report

Original Paper

Is susceptibility locus for lung cancer in the 15q25 nicotinic acetylcholine receptor gene cluster CHRNA5-A3-B4 associated with risk of gastric cancer?

Review Article

Integrating complementary medicine in supportive cancer care models across four continents

Original Paper

Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma

Original Paper

Polymorphic CT dinucleotide repeat in the GATA3 gene and risk of breast cancer in Iranian women

Letter to the Editor

Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits